VEGFA and glioblastoma: Consistently, there is no benefit if imipramine is excluded in our GBM models, thus mirroring clinical experiences involving VEGF pathway inhibitors and immune-checkpoint inhibitors, either alone or in combination (NCT02337491, NCT03291314).